Duell, J., Lukic, D.S., Karg, M., Reusch, U., Koch, J., Zhukovsky, E.A., Rajkovic, E., Treder, M., Rasche, L., Eisele, F., Einsele, H. and Topp, M.S. (2019) Functionally Defective T Cells after Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11. Journal of Immunotherapy, 42, 180-188.
https://doi.org/10.1097/CJI.0000000000000267

has been cited by the following article:

• TITLE: Construction of Multi-Specific Antibody by Genetic Engineering and Its Progress in Tumor Therapy

  AUTHORS: Zhenqi Xu, Can Gao, Mengru Jian, Wei Du

  KEYWORDS: Genetically Engineered, Multi-Specific Antibody, Tumor Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 24, 2023

  ABSTRACT: Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.